Evidence map›Paper›PMID 42606614›Full record

ArticleMolecular biology reports2026

Pediatric cystic fibrosis is associated with type 3 immune response.

Tuğba Nur Gür, Zehra Buşra Azizoğlu, Yesim Haliloğlu, Fatma Zehra Okuş, Şerife Erdem, Melih Hangül, Mehmet Köse, Ahmet Eken, Halit Canatan

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tuğba Nur GürDepartment of Medical Biology, Institute of Health Sciences, Kayseri, Turkey.ORCID http://orcid.org/0000-0002-6048-1550
Zehra Buşra AzizoğluDepartment of Medical Biology, School of Medicine, Erciyes University, Kayseri, 38030, Turkey.ORCID http://orcid.org/0000-0001-5183-9015
Yesim HaliloğluDepartment of Medical Biology, School of Medicine, Erciyes University, Kayseri, 38030, Turkey.ORCID http://orcid.org/0000-0002-2942-5358
Fatma Zehra OkuşDepartment of Medical Biology, Institute of Health Sciences, Kayseri, Turkey.ORCID http://orcid.org/0000-0001-7106-3840
Şerife ErdemDepartment of Medical Biology, School of Medicine, Erciyes University, Kayseri, 38030, Turkey.ORCID http://orcid.org/0000-0002-2255-1685
Melih HangülDepartment of Pediatrics, School of Medicine, Erciyes University, Kayseri, Turkey.ORCID http://orcid.org/0000-0001-6226-0340
Mehmet KöseDepartment of Pediatrics, School of Medicine, Erciyes University, Kayseri, Turkey.ORCID http://orcid.org/0000-0002-3003-918X
Ahmet EkenDepartment of Medical Biology, Institute of Health Sciences, Kayseri, Turkey. ahmet.eken@gmail.com.ORCID http://orcid.org/0000-0002-5816-0686
Halit CanatanDepartment of Medical Biology, Institute of Health Sciences, Kayseri, Turkey. halitcanatan@yahoo.com.ORCID http://orcid.org/0000-0002-0978-8311

Funding

Erciyes University Scientific Research Projects Coordination (BAP) Unit TYL-2019-9445
6 · The paper itself

Abstract

backgroundCystic fibrosis (CF) is an autosomal recessive disorder caused by pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CFTR dysfunction impairs epithelial chloride and bicarbonate transport, leading to dehydrated airway surfaces, mucus accumulation, defective mucociliary clearance, and chronic inflammation. Type 3 immune responses, particularly those involving IL-17 A and IL-22, have been implicated in CF airway disease; however, systemic alterations in these pathways remain incompletely defined, especially in pediatric patients.

methodsPeripheral blood samples were obtained from healthy controls (n = 20), pediatric patients with clinically stable CF (n = 20), and pediatric patients with CF experiencing pulmonary exacerbation (n = 8). Peripheral blood mononuclear cells were isolated by Ficoll-Hypaque density-gradient centrifugation. Following stimulation with phorbol 12-myristate 13-acetate and ionomycin, intracellular IL-17 A, IL-22, and IL-10 production was assessed by flow cytometry in CD3-positive and CD3-negative lymphocyte populations. Plasma IL-17 A, IL-22, and granulocyte-macrophage colony-stimulating factor levels were measured by enzyme-linked immunosorbent assay.

resultsThe percentage of lymphocytes was higher in patients with stable CF than in healthy controls and patients experiencing pulmonary exacerbation, whereas absolute lymphocyte numbers were comparable among groups. The absolute number of CD3⁺IL-22⁺ cells was increased in patients with stable CF compared with healthy controls. Both the frequency and absolute number of CD3⁻IL-22⁺ cells were increased in patients with stable CF, while the frequency of CD3⁻IL-22⁺ cells was also increased during pulmonary exacerbation. Plasma IL-17 A concentrations were lower in patients with stable CF than in healthy controls. In addition, the absolute number of CD3⁺IL-10⁺ cells was increased in patients with stable CF. No statistically significant differences were detected in plasma IL-22 or granulocyte-macrophage colony-stimulating factor concentrations.

conclusionsPediatric CF is associated with selective alterations in circulating type 3 and regulatory immune responses, characterized by increased IL-22-producing lymphocyte populations, reduced plasma IL-17 A concentrations, and increased numbers of CD3⁺IL-10⁺ cells. These findings suggest that systemic immune regulation in CF differs between stable disease and pulmonary exacerbation and warrant confirmation in larger longitudinal cohorts.

Indexed as

Cystic FibrosisAdolescentCase-Control StudiesChildChild, PreschoolCystic Fibrosis Transmembrane Conductance RegulatorFemaleGranulocyte-Macrophage Colony-Stimulating FactorHumansInterleukin-10Interleukin-17Interleukin-22InterleukinsLeukocytes, MononuclearMaleCFTR protein, humanCystic Fibrosis Transmembrane Conductance RegulatorGranulocyte-Macrophage Colony-Stimulating FactorIL17A protein, humanInterleukin-10Interleukin-17Interleukin-22InterleukinsCFTRCystic fibrosisIL-10IL-17AIL-22Pulmonary exacerbationType 3 immunity

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.